Abstract
Background A claimed advantage of colonoscopy over sigmoidoscopy in colorectal cancer (CRC) screening is prevention of CRC not only in the distal colon and rectum but also in the proximal colon. We aimed to assess the association of screening colonoscopy use with overall and site-specific CRC incidence and associated mortality.
Methods Information on use of screening colonoscopy as well as potential confounding factors was obtained at baseline in 2000-2002, updated at 2-, 5-, and 8-year follow-up from 9207 participants aged 50-75 years without history of CRC in a statewide cohort study in Saarland, Germany. Covariate-adjusted associations of screening colonoscopy with CRC incidence and mortality, which were obtained through record linkage with the Saarland Cancer Registry and mortality statistics up to 2016, were assessed by Cox proportional hazards models with time-varying exposure information.
Findings During a median follow-up of 15·3 years, 227 participants were diagnosed with CRC and 81 died from CRC. Screening colonoscopy was associated with strongly reduced overall CRC incidence (adjusted hazard ratio, aHR 0·54, 95% confidence interval, CI 0·41-0·72) and mortality (aHR 0·39, 95% CI 0·24-0·63). However, strong incidence and mortality reduction was seen for distal CRC (aHRs 0·44, 95% CI 0·30-0·63, and 0·35, 95% CI 0·19-0·66, respectively) only, but not for proximal CRC (aHRs 0·99, 95% CI 0·58-1·68, and 0·72, 95% CI 0·29-1·81, respectively).
Conclusion In this large prospective cohort study from Germany, screening colonoscopy was associated with strong reduction in total and distal CRC incidence and mortality, but no reduction was seen for cancer incidence and mortality in the proximal colon.
Evidence before this study
Multiple randomized controlled trials have demonstrated that screening with flexible sigmoidoscopy can substantially reduce incidence and mortality from cancer in the distal colon and rectum.
Evidence on the impact of screening colonoscopy on colorectal cancer incidence and mortality from randomized trials is lacking, and evidence from prospective cohort studies is very limited.
In particular, it is highly uncertain to what extent screening colonoscopy can additionally reduce incidence and mortality from cancer in the proximal colon.
Added value of this study
This population-based, prospective statewide cohort study from Saarland/Germany with repeat updates of exposure information demonstrates major reduction of total and distal CRC incidence and mortality among people who underwent screening colonoscopy.
However, no reduction of incidence and mortality from cancer in the proximal colon was observed.
These results challenge the expectation of incremental effectiveness of colonoscopy screening over screening by flexible sigmoidoscopy in preventing colorectal cancer.
Implications of all the available evidence
Our results may impact on recommendations, offers and use of colonoscopy versus flexible sigmoidoscopy for colorectal cancer screening.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Baden-Württemberg State Ministry of Science, Research and Arts, the German Federal Ministry of Education and Research, the German Federal Ministry of Family, Senior Citizens, Women and Youth, the Saarland State Ministry of Social Affairs, Health, Women and Family, and the German Cancer Aid (No. 70112095).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Anonymized data relevant to the study may be provided upon reasonable request for uses that are compatible with participants’ informed consent.
